No Picture
News

Little Conatus’ Novartis-partnered liver drug suffers third straight defeat, but CEO Mento is still holding out hope

Little Conatus’ Novartis-partnered liver drug is one step closer to the scrap heap, with its third mid-stage failure.
The Swiss drugmaker handed the San Diego-based biotech $50 million upfront and an injection of confidence in late 2016 to license the … […]